Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences' stock outlook is bolstered by robust sales driven by increasing demand and effective market share gains, exemplified by Biktarvy’s rise to 52% market share in the U.S. HIV market, up from 49% in the previous quarter. The company has strengthened its growth guidance for HIV to +5% year-over-year, despite challenges from anticipated Medicare Part D headwinds, along with projected additional sales increases of approximately $500 million by 2026. Furthermore, Gilead’s positioning in the oncology market, driven by innovative treatments and collaborations, suggests continued revenue growth potential across multiple therapeutic areas.

Gilead Sciences is experiencing a notable decline in sales across several key therapeutic areas, with Trodelvy sales slightly decreasing to $357 million and a projected 10% decline in cell therapy revenue from FY2024 to FY2025. Veklury revenue significantly underperformed at $277 million, representing a 60% year-over-year decrease, which prompted Gilead to lower its FY2025 revenue guidance from $1.4 billion to $1.0 billion due to reduced COVID hospitalization rates. Additionally, ongoing competitive pressures have adversely impacted cell therapy revenue, which declined by 11% year-over-year, contributing to a broader negative outlook on the company's financial performance.